Very early researchStudy completedNCT03281811What this trial is testingPhotodynamic Therapy in Treating Patients With Refractory Mycosis FungoidesWho this might be right forRefractory Mycosis Fungoides Mayo Clinic 11
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07032532What this trial is testingAssessing An Oral JAK1 Inhibitor, Golidocitinib, in Patients Who Have Newly Diagnosed Peripheral T-Cell Lymphoma (JACKPOT23)Who this might be right forPeripheral T Cell Lymphoma Sun Yat-sen University 35
Testing effectiveness (Phase 2)UnknownNCT05749549What this trial is testingPhase I/IIa Study of BR1733 in Subjects With Advanced CancersWho this might be right forAdvanced CancerFollicular LymphomaPeripheral T Cell Lymphoma+1 more Shanghai Blueray Biopharma Co., Ltd. 191
Early research (Phase 1)Study completedNCT04067414What this trial is testingExploratory Study of CD19-targeted Chimeric Antigen Receptor T Cells(BZ019) for Relapsed and Refractory B-cell LymphomaWho this might be right forDiffuse Large B Cell LymphomaHigh-grade B-cell LymphomaTransformed Lymphoma+1 more Institute of Hematology & Blood Diseases Hospital, China 12
Testing effectiveness (Phase 2)Study completedNCT00901147What this trial is testingStudy of Bortezomib and Panobinostat in Treating Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or NK/T-cell LymphomaWho this might be right forPeripheral T-cell Lymphoma (Not Otherwise Specified)Angioimmunoblastic T-cell LymphomaExtranodal NK/T-cell Lymphoma Nasal Type+4 more Singapore General Hospital 25
Testing effectiveness (Phase 2)Study completedNCT02273739What this trial is testingStudy of Orally Administered Enasidenib (AG-221) in Adults With Advanced Solid Tumors, Including Glioma, or Angioimmunoblastic T-cell Lymphoma, With an IDH2 MutationWho this might be right forSolid TumorGliomaAngioimmunoblastic T-cell Lymphoma+2 more Celgene 21
Very early researchUnknownNCT03661554What this trial is testingBCMA Nano Antibody CAR-T Cells for Patients With Refractory and Relapsed Multiple MyelomaWho this might be right forRelapsed and Refractory Multiple Myeloma The Pregene (ShenZhen) Biotechnology Company, Ltd. 15
Early research (Phase 1)Study completedNCT02924402What this trial is testingStudy to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic MalignanciesWho this might be right forB-cell Non-Hodgkins LymphomaChronic Lymphocytic Leukemia Xencor, Inc. 154
Early research (Phase 1)Ended earlyNCT06254495What this trial is testingA Safety Study of PF-08046044/SGN-35C in Adults With Advanced CancersWho this might be right forHodgkin DiseaseLymphoma, T-Cell, PeripheralLymphoma, Large B-Cell, Diffuse+1 more Seagen, a wholly owned subsidiary of Pfizer 58
Testing effectiveness (Phase 2)Active Not RecruitingNCT05801939What this trial is testingCevostamab Following CAR T Cell Therapy for RRMMWho this might be right forRelapsed/Refractory Multiple Myeloma University of Pennsylvania 30
Very early researchUnknownNCT04264039What this trial is testingAnti-CD19 U-CAR-T Cell Therapy for B Cell Hematologic MalignanciesWho this might be right forB-cell Acute Lymphoblastic LeukemiaB-cell Lymphoma Xinqiao Hospital of Chongqing 30
Not applicableLooking for participantsNCT03375619What this trial is testingLong-term Follow-up Study of Patients Receiving CAR-T CellsWho this might be right forChronic Lymphocytic LeukemiaLymphomas Non-Hodgkin's B-CellLymphoma, Small Lymphocytic+6 more Medical College of Wisconsin 500
Not applicableNot Yet RecruitingNCT07198373What this trial is testingExploratory Study on the Efficacy of Zebutinib as Maintenance Therapy Following CAR-T Cell Therapy in Patients With Non-Hodgkin B-Cell LymphomaWho this might be right forB Cell Lymphoma Beijing GoBroad Hospital 40
Testing effectiveness (Phase 2)UnknownNCT03502629What this trial is testingClinical Trial in Chinese Patients of Relapsed and Refractory Peripheral T Cell Lymphoma (GB226)Who this might be right forPeripheral T Cell Lymphoma Genor Biopharma Co., Ltd. 86
Very early researchUnknownNCT06067581What this trial is testingThe Safety and Efficacy of SENL103 Autologous T Cell InjectionWho this might be right forMultiple Myeloma Hebei Senlang Biotechnology Inc., Ltd. 20
Testing effectiveness (Phase 2)Looking for participantsNCT06235229What this trial is testingGC012F in Patients With Relapsed/Refractory Multiple MyelomaWho this might be right forMultiple Myeloma Gracell Biotechnologies (Shanghai) Co., Ltd. 110
Very early researchLooking for participantsNCT07048353What this trial is testingCD30 CAR-T in the Treatment of CD30 Positive LymphomaWho this might be right forLymphomaB Cell LymphomaCD30+ Peripheral T-cell Lymphoma Shandong Qilu Cell Therapy Engineering Technology Co., Ltd 15
Testing effectiveness (Phase 2)Ended earlyNCT00112723What this trial is testingFlavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple MyelomaWho this might be right forAdult Lymphocyte Depletion Hodgkin LymphomaAdult Lymphocyte Predominant Hodgkin LymphomaAdult Mixed Cellularity Hodgkin Lymphoma+25 more National Cancer Institute (NCI) 46
Testing effectiveness (Phase 2)Looking for participantsNCT06495723What this trial is testingPolyspecific Antibodies in Lymphoproliferative T-cell DisordersWho this might be right forPeripheral T Cells Lymphoma (PTCL) Xenothera SAS 54
Testing effectiveness (Phase 2)UnknownNCT04935580What this trial is testingStudy of FasT CAR-T GC012F Injection in High Risk TE NDMM PatientsWho this might be right forMultiple Myeloma Shanghai Changzheng Hospital 20